

Anti-HLA-G Reference Antibody (Roche patent anti-HLA-G)

Catalog # APR11365

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P17693
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	38224

Additional Information

Target/Specificity	HLA-G
Expression system	CHO

Protein Information

Name	HLA-G {ECO:0000303 PubMed:1570318, ECO:0000312 HGNC:HGNC:4964}
Function	[Isoform 1]: Non-classical major histocompatibility class Ib molecule involved in immune regulatory processes at the maternal-fetal interface (PubMed:19304799, PubMed:23184984, PubMed:29262349). In complex with B2M/beta-2 microglobulin binds a limited repertoire of nonamer self-peptides derived from intracellular proteins including histones and ribosomal proteins (PubMed:7584149, PubMed:8805247). Peptide-bound HLA-G-B2M complex acts as a ligand for inhibitory/activating KIR2DL4, LILRB1 and LILRB2 receptors on uterine immune cells to promote fetal development while maintaining maternal- fetal tolerance (PubMed:16366734, PubMed:19304799, PubMed:20448110, PubMed:23184984, PubMed:27859042, PubMed:29262349). Upon interaction with KIR2DL4 and LILRB1 receptors on decidual NK cells, it triggers NK cell senescence-associated secretory phenotype as a molecular switch to promote vascular remodeling and fetal growth in early pregnancy (PubMed:16366734, PubMed:19304799, PubMed:23184984, PubMed:29262349). Through interaction with KIR2DL4 receptor on decidual macrophages induces pro-inflammatory cytokine production mainly associated with tissue remodeling (PubMed:19304799). Through interaction with LILRB2 receptor triggers differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance (PubMed:20448110, PubMed:27859042). May play a role in balancing tolerance and antiviral-immunity at maternal-fetal interface by keeping in check the effector functions of NK, CD8+ T cells and B cells (PubMed:10190900, PubMed:11290782, PubMed:24453251). Reprograms B cells toward an immune suppressive

phenotype via LILRB1 (PubMed:[24453251](#)). May induce immune activation/suppression via intercellular membrane transfer (troglcytosis), likely enabling interaction with KIR2DL4, which resides mostly in endosomes (PubMed:[20179272](#), PubMed:[26460007](#)). Through interaction with the inhibitory receptor CD160 on endothelial cells may control angiogenesis in immune privileged sites (PubMed:[16809620](#)).


Cellular Location

[Isoform 1]: Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane. Early endosome membrane [Isoform 2]: Cell membrane; Single-pass type I membrane protein [Isoform 4]: Cell membrane; Single-pass type I membrane protein [Isoform 6]: Secreted Cell projection, filopodium membrane. Note=HLA-G troglcytosis from extravillous trophoblast's filopodia occurs in the majority of decidual NK cells.


Tissue Location

Expressed in adult eye (PubMed:1570318). Expressed in immune cell subsets including monocytes, myeloid and plasmacytoid dendritic cells and regulatory T cells (Tr1)(at protein level) (PubMed:20448110). Secreted by follicular dendritic cell and follicular helper T cells (PubMed:24453251) [Isoform 7]: Expressed in placenta, amniotic membrane, skin, cord blood and peripheral blood mononuclear cells


Images



Anti-HLA-G Reference Antibody (Roche patent anti-HLA-G) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti-HLA-G Reference Antibody (Roche patent anti-HLA-G) is 100%, determined by SEC-HPLC.



HLA-G/A375 cell line were stained with Roche patent anti-HLA-G and negative control protein respectively, washed and then followed by PE and analyzed with FACS, with the EC50 is 2.971 nM.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.